Response as an end point in treatment trials for acute GVHD
Author:
- 8 February 2012
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 47 (2) , 161-163
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Reduced Mortality after Allogeneic Hematopoietic-Cell TransplantationNew England Journal of Medicine, 2010
- Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease: A Joint StatementTransplantation and Cellular Therapy, 2009
- Prophylaxis regimens for GVHD: systematic review and meta-analysisBone Marrow Transplantation, 2008
- Study design and endpoints in graft-versus-host diseaseBest Practice & Research Clinical Haematology, 2008
- Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host diseaseBlood, 2008
- A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host diseaseBlood, 2007
- Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trialsBone Marrow Transplantation, 2006
- IBMTR Severity INDEX FOR GRADING ACUTE GRAFT‐VERSUS‐HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADEBritish Journal of Haematology, 1997
- A retrospective analysis of therapy for acute graft-versus-host disease: initial treatmentBlood, 1990
- Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcomeBlood, 1990